Novel polymorphous form and the amorphous form of 5-chloro-N- ({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}- methyl)-2-thiophene carboxamide

Details for Australian Patent Application No. 2006299126 (hide)

Owner Bayer Pharma Aktiengesellschaft

Inventors Grunenberg, Alfons; Thomas, Christian R.; Braun, Gerhard Arnold; Lenz, Jana; Keil, Birgit

Agent Davies Collison Cave

Pub. Number AU-B-2006299126

PCT Pub. Number WO2007/039132

Priority 10 2005 047 563.9 04.10.05 DE; 10 2005 047 564.7 04.10.05 DE

Filing date 22 September 2006

Wipo publication date 12 April 2007

Acceptance publication date 28 June 2012

International Classifications

C07D 413/14 Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

A61K 31/5377

A61P 7/02 Drugs for disorders of the blood or the extracellular fluid

Event Publications

1 May 2008 PCT application entered the National Phase

  PCT publication WO2007/039132 Priority application(s): WO2007/039132

14 May 2009 Assignment before Grant

  Bayer HealthCare AG The application has been assigned to Bayer Schering Pharma Aktiengesellschaft

28 June 2012 Application Accepted

  Published as AU-B-2006299126

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006299127-Two-component systems for producing flexible coatings

2006299115-Photostable pharmaceutical composition containing brivudine for the treatment of herpetic keratitis